---
schema_version: "secwatch.filing_event.v1"
accession: "0000882095-26-000003"
form_type: "8-K"
ticker: "GILD"
cik: "0000882095"
company_name: "GILEAD SCIENCES, INC."
filed_at: "2026-02-10T23:59:59+00:00"
generated_at: "2026-05-16T03:45:38.376027+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Gilead Q4/FY2025: revenue up 5% to $7.9B Q4, full-year EPS $6.78; guides 2026 sales $29.6-30B

## Summary
- Q4 GAAP diluted EPS $1.74 vs $1.42 YoY; non-GAAP diluted EPS $1.86 vs $1.90.
- Q4 product sales up 5% to $7.9B; HIV sales up 6% to $5.8B; Biktarvy $4.0B (+5%).
- Full year 2025 total revenues $29.4B (+2%); product sales ex-Veklury $28.0B (+4%).
- Full year GAAP diluted EPS $6.78 vs $0.38; non-GAAP $8.15 vs $4.62.
- FY2026 guidance: product sales $29.6-30B, non-GAAP diluted EPS $8.45-8.85.

## SEC filing metadata
- accession: 0000882095-26-000003
- form_type: 8-K
- ticker: GILD
- cik: 0000882095
- company_name: GILEAD SCIENCES, INC.
- filed_at: 2026-02-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882095/000088209526000003/0000882095-26-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882095/000088209526000003/gild-20260210.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000882095-26-000003
- JSON: https://secwatch.observer/filing/0000882095-26-000003.json
- Plain text: https://secwatch.observer/filing/0000882095-26-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.